President and CEO
Søren Tulstrup has a broad and extensive background as senior executive in the global biopharma industry. Recently, he served as CEO of Vifor Pharma AG (VTX:VIFN), a Glattbrugg, Switzerland-based global pharmaceutical company with a market-leading position within chronic kidney disease, annual sales of approximately USD 1 billion and 2,000 employees. Prior to joining Vifor Pharma, he served as Senior Vice President, Global Franchise Head, MPS at Shire Pharmaceuticals, securing strong market performance of Elaprase (INN: Idursulfase), an enzyme-based treatment of the rare disease Hunter syndrome. Søren has also served as CEO of Santaris Pharma A/S, now part of Roche, a leading clinical stage biopharmaceutical company developing RNA-targeted drugs for various therapeutic areas including cancer and rare genetic diseases. Furthermore, Søren has served in several senior commercial roles within Merck & Co., Inc. and Sandoz Pharma AG (Novartis) and he holds a Master of Science, Economics and Business Administration from Copenhagen Business School. Born 1965.